NCT05859724

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 126 (actual)
• Sponsor: Yellow Jersey Therapeutics AG · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single (SAD) and multiple doses (MAD) of NM26-2198.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
BIOLOGICAL	NM26-2198	IL-4R/IL-31 bispecific antibody for subcutaneous administration
OTHER	Placebo	Placebo for NM26-2198

Timeline

• Start date: 2023-05-10
• Primary completion: 2024-10-01
• Completion: 2024-10-17
• First posted: 2023-05-16
• Last updated: 2026-04-13

Locations

15 sites across 4 countries: United States, Canada, Germany, Poland

Regulatory

• FDA-regulated drug study